Abstract

Background: Cigarette smoke with its toxic ingredients leads to chronic inflammations in the airways.

Objectives: In this study, the effect of cigarette smoke on the levels of inflammatory markers, interleukin-6 (IL-6), interleukin-8 (IL-8), and tumor necrosis factor-alpha (TNF-α) in induced sputum was investigated.

Materials and Methods: Twenty patients with chronic obstructive pulmonary disease (COPD) (group I), 20 healthy smokers (group II), and 20 healthy nonsmokers (group III) were included in the study. The levels of IL-6, IL-8, and TNF-α in induced sputum were measured in these groups, and comparison analysis between the groups and correlation analysis for smoking load (pack-years) and spirometric parameters were performed.

Results: Mean age of the patients in groups I, II, and III were 61.2 ± 1.7, 58.2 ± 1.6, and 59.1 ± 5.4 years, respectively (P > 0.05). Smoking loads of group I and group II were 38.6 ± 2.1 and 29.5 ± 2.3 pack-years, respectively (P < 0.05). All cytokine levels were significantly higher in group I than groups II and III (P < 0.05). In addition to this, mean cytokines levels were significantly higher in group II than group III (P < 0.05). Smoking load of group II subjects was positively correlated with IL-6, IL-8, and TNF-α in induced sputum (P < 0.05).

Conclusions: We found that inflammatory marker levels in induced sputum were significantly higher in COPD patients and smokers than nonsmokers. Moreover, there was a moderate positive correlation between IL-6, IL-8, and TNF-α levels and smoking load in the healthy smokers. We think that further studies are needed to determine whether higher levels of cytokine levels in sputum might be helpful in predicting the healthy smokers who will develop COPD in future.

Keywords: Chronic obstructive pulmonary disease, inflammatory markers, induced sputum, IL-6, IL-8, TNF-α

Date of Acceptance: 22-May-2012

Introduction

Cigarette smoking is by far the most commonly encountered risk factor for chronic obstructive pulmonary disease (COPD). Cigarette smokers have a higher prevalence of respiratory symptoms and lung function abnormalities, a greater annual rate of decline in FEV₁, and a greater COPD mortality rate than nonsmokers. These differences between smokers and nonsmokers show direct correlation with the smoking load (pack-years). Patients should be identified as early in the course of the disease as possible and certainly before the end stage of the illness when disability is substantial. Access to spirometry is key to the diagnosis of COPD. However, the benefits of community-based spirometric screening, of either the general population or smokers, are still unclear. Therefore, it is necessary to find sensible parameters to detect early lung alterations due to chronic tobacco smoke exposure. Long-term cigarette smoking is associated with a persistent inflammatory response in the lung that leads to tissue injury and dysfunction. Induced sputum are validated noninvasive techniques for assessing respiratory inflammation. This approach could enable an early identification of subgroups of healthy smokers at higher risk for tobacco-induced lung

Address for correspondence:
Dr. Suleyman Savas Hacievliyagil,
Department of Pulmonary Disease, Inonu University, Turgut Ozal Medical Center, 44069 Malatya, Turkey.
E-mail: suleyman.hacievliyagil@inonu.edu.tr
It was also showed that TNF-α (IL-6) is thought to play a role in all types of acute lung inflammation through its stimulatory effects on lymphocytes and the acute phase response. Interleukin-8 (IL-8), a CXC chemokine, is an important neutrophil chemoattractant and activator. Tumor necrosis factor-alpha (TNF-α) is also proinflammatory cytokine. These cytokines have been shown to be important markers of inflammation and play key roles in the persistence of inflammatory process in COPD.\[^{2,3}\]

It was previously showed that COPD patients had higher serum levels of TNF-α, IL-8, and IL-6 than healthy control subjects.\[^{4}\] It was also showed that TNF-α, IL-6, and IL-8 levels were found in increased amounts in the sputum and exhaled breath of patients with COPD, particularly during exacerbations.\[^{5,7}\]

Chronic inflammation in the airways of individuals who smoke persists even after smoking cessation. We aimed to show whether COPD patients who continue to smoke has higher levels of IL-6 level, IL-8 level, and TNF-α than current healthy smokers and nonsmokers. We also aimed to analyze whether cytokine levels in induced sputum show any relationship with smoking load and the severity of airway obstruction.

**Materials and Methods**

Twenty current smokers with stable COPD (group I) and 40 age-matched healthy control subjects [20 current smokers (group II) and 20 nonsmokers (group III)] were included in the study. Twenty healthy individuals were taken as control group in study. Their age and sex characteristics were similar to the groups. The study was carried out at the outpatient clinics of pulmonary medicine, Turgut Ozal Research Center of Inonu University, Malatya, Turkey. The study protocol was approved by the Ethics Committee of the center, and informed consent was obtained from all the participants. Pulmonary function tests (PFT) were performed in all cases using the Vmax 22 device (Sensor Medics, Yorba Linda, CA, USA). In clinically compatible patients, COPD was defined as a postbronchodilator FEV\(_1\)/FVC ratio of <70%.\[^{1}\]

All COPD patients who were admitted to our outpatient clinics for an acute exacerbation were exclusion criteria in the study. All COPD patients were included in the study and were treated in a standard inhaled bronchodilators (inhaled long-acting antimuscarinic [tiotropium bromide 18 µg per capsule, one inhalation once daily], inhaled corticosteroid and long-acting β agonist [budesonide 160/320 µg/inhalation and formoterol fumarate dihydrate 4.5/9 µg/inhalation, one inhalation twice daily], inhaled short-acting bronchodilator [albuterol sulfate 100 µg/inhalation and ipratropium bromide 20 µg/inhalation, if required] and if supplemental oxygen. They were no medications except for COPD. The COPD patients were not enrolled at all if they had an exacerbation or utilization of systemic form of corticosteroid preparations (oral or intravenous injection therapy) within 1 month prior to the study entry. Antibiotics were not used where signs of bacterial infection existed. Since our long-term treatment policy for the patients with COPD did not include administration of maintenance oral corticosteroids, we did not see any COPD patients utilizing oral or intravenous corticosteroid therapy during the study period in the region. COPD patients admitted with specific reasons like pneumonia, pulmonary emboli, congestive heart failure, lung cancer, etc., were not included. All subjects had no other pulmonary disease including asthma, bronchiectasia, pneumonia, tuberculosis, or lung cancer. Additionally, patients with respiratory failure were not admitted to the Intensive Care Unit. In addition to this, while groups II and III patients were not utilizing any type of medication, COPD patients were also not utilizing any kind of medication, including theophylline preparations, diuretics, mucolytics, antibiotics, etc., other than inhaled bronchodilators. Posteroanterior chest films were obtained from all patients, and no abnormality was detected in the participants other than the patients with COPD. In their recent and past medical history, healthy smokers and nonsmokers did not describe any disease state which may interfere with their pulmonary functions. Smoking history [pack-years (number of cigarette packs per day multiplied by duration of smoking in years)] was taken from all group I and group II subjects.

Induced sputum samples were obtained from the subjects by means of ultrasonic nebulizers (Hirtz, Hico-Ultrasound 806 EH, Köln-Germany). For this purpose, patients were instructed to rinse their mouths with water after inhalation of a 3% saline solution for 5-7 minutes, and then asked to expectorate deeply for the 2 ml induced sputum samples to be collected. After 7 min of nebulization, measurement of oxygen saturation and spirometric tests were performed and nebulization continued if the FEV\(_1\) had not fallen by more than 20%. In patients in whom adequate amount of sputum sample could not be collected, saline inhalation was repeated at the same dose after further 7 min and the procedure stopped. The samples that were collected in wide-covered sterile 50 cc polypropylene plastic cups were immediately transferred to the laboratory after labeling for processing. The induced sputum samples were examined as soon as possible within an hour. The sputum samples were prevented from contamination with saliva by filtering through...
double-layered sterile gauze immediately after collection. With the aid of a forceps and spatula approximately 1-1.5 g of sputum was taken from each sample and transferred into 10 ml sterile polypropylene tubes with predetermined weights and reweighed. After the addition of a phosphate buffer solution (PBS) that weighed nine times their fresh weight, 5-6 pieces of silicone glass beads were introduced into each tube and stirred with a vortex for 10 min until a homogenized solution was obtained. The solution was thereafter subjected to centrifugation at +4°C for 10 min at 1000 rpm. The resulting supernatant was transported into polypropylene tubes in aliquots of 1ml. After the addition of 10 ml 100 mM phenyl methyl sulfonyl fluoride (PMSF) into each tube, they were covered and turned upside down several times to ensure adequate mixing. The supernatant decanted off and stored at −70°C. [8,9]

The IL-6, IL-8, and TNF-α levels were measured by the chemiluminescence method using an Immulite-1000 analyzer and special kits (DPC [Diagnostic Product Co., CA, USA]). The lower limit of detection for these assays was 5 pg/ml for IL-6, 2 pg/ml for IL-8, and 5 pg/ml for TNF-α. The interassay and intraassay coefficients of variation of the all assays were less than 10%.

All statistical analyses were performed using SPSS 13.0 for Windows (SPSS, Inc., Chicago, IL, USA). Group data were expressed as means ± SEM. The data were tested for normality, non-normal data were transformed. Differences between the groups were tested using the Kruskal-Wallis test. Correlation between cytokine levels and different parameters (smoking load and spirometric parameters) was analyzed using Spearman’s rank correlation coefficient. A P value < 0.05 was considered statistically significant.

Results

The mean age of the COPD patients (group I), current healthy smokers (group II), and nonsmokers (group III) were 61.2 ± 1.7, 58.2 ± 1.6, and 59.1 ± 5.4 years, respectively (P > 0.05). Group I and group II subjects had mean smoking load of 38.6 ± 2.1 and 29.5 ± 2.3 pack-years, respectively (P = 0.007). Of the COPD patients, 3 subjects fulfilled the criteria for GOLD stage I, 6 subjects were GOLD stage II, 10 subjects were GOLD stage III, and 1 subject were GOLD stage IV.

The PFT results for groups are shown in Table 1. Although group II patients are healthy subjects, their spirometric values were significantly lower than the group III subjects. However, their spirometric values were found within the normal range. Patients with COPD and other participants did not report any adverse event or worsening dyspnea upon induction of sputum. No significant change in FEV₁ before and after the inhalation of hypertonic saline occurred.

The levels of IL-6 in the induced sputum were 393.6 ± 107.2 pg/ml for group I, 88.5 ± 23.8 pg/ml for group II, and 7.4 ± 1.3 pg/ml for group III. The mean induced sputum IL-8 levels for groups I, II, and III were 6541.7 ± 861.0, 2717.4 ± 632.7, and 385.9 ± 30.1 pg/ml, respectively. TNF-α levels in the induced sputum were found to be 90.8 ± 19.6, 36.3 ± 5.7, and 13.7 ± 0.4 pg/ml for groups I, II, and III, respectively. Comparison of all cytokine levels in induced sputum yielded statistically significant results between groups (P < 0.001). Smoking load of group II subjects was positively correlated with IL-6, IL-8, and TNF-α in induced sputum (r = 0.567, P = 0.009; r = 0.646, P = 0.002; r = 0.491, P = 0.028, [Figures 1–3]).

Discussion

Cigarette smoking is accepted to be the most important cause of COPD, but only some smokers will develop clinically overt disease. Probably, the inflammation caused by cigarette smoke interacts with other host and/or environmental factors to produce the excess decline in lung function which results in COPD.[11] There are numerous studies investigating the relationship between cigarette smoke and airway inflammation.[12,13] In the present study, all cytokine levels in induced sputum were found higher in COPD patients than healthy smokers and nonsmokers, as well as these levels was found higher in healthy smokers than nonsmokers. In addition to these, the levels of IL-6, IL-8, and TNF-α were positively correlated with smoking load (pack-years) only in healthy smoker group but not in COPD group.

Cigarette smoke activates alveolar macrophages and epithelial cells to release inflammatory mediators such as TNF-α and IL-8.[12,13] Mio et al. showed that bronchial epithelial cells isolated from major bronchi responded to tobacco smoke to release IL-8.[14] Takizawa et al. found high levels of IL-8 mRNA and spontaneous release of IL-8...
protein in small-airway epithelial cells in smokers compared with that in nonsmokers. Wang et al. measured the induced sputum IL-6, IL-8, and TNF-α levels in 20 patients with stable COPD and compared them with smoking and nonsmoking control groups. While the IL-8 and TNF-α levels in the COPD group were found to be significantly higher than the smoking and nonsmoking groups, IL-8 level in the smoking group was also found significantly higher than the nonsmoking group. The IL-6 levels, however, did not show any significant differences between the groups. Similarly, we also found the same results regarding IL-8 and TNF-α levels with one difference that IL-6 levels were also significantly higher in the smoking groups than the nonsmoking group and in the COPD group than the others. On the other hand, we found that healthy smoker group’s inflammatory markers were higher from the nonsmoker group but lower from the COPD group. It is unclear if the IL-6, IL-8, and TNF-α levels in COPD and healthy smoking group were also higher before they started to smoke or they had given a higher inflammatory response to smoking. Like most of the previous studies our study was also a cross sectional. To understand this, long-term prospective investigations should be done.

There are numerous studies in the literature which investigated the relationship between cytokine levels in the airways and spirometric parameters. Yamamoto et al. reported a negative correlation between the IL-8 levels in induced sputum and the FEV1/FVC ratio in COPD patients. In another study, FEV1 was found to be inversely correlating with IL-6 and IL-8 concentrations in bronchoalveolar lavage (BAL) fluid. In addition to these, Kanazawa et al. found a positive correlation between the serum IL-8 level and the annual rate of fall in FEV1 ratio. However, in a similar way with the study by Bhowmik et al., we also could not establish any relationship between cytokine levels in induced sputum and spirometric parameters in our study. We think that methodological variations between the studies mentioned above and limited number of participants in each study might have displayed these different results. The relationship of cytokine levels in the airways with smoking load has been vigorously investigated by several clinicians.

Table 1: The comparison of general characteristics, spirometric parameters, and cytokines levels in induced sputum between the groups

<table>
<thead>
<tr>
<th></th>
<th>Group 1 (COPD)</th>
<th>Group 2 (healthy smokers)</th>
<th>Group 3 (healthy nonsmokers)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of subjects</td>
<td>20</td>
<td>20</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>61.2±1.7</td>
<td>58.2±1.6</td>
<td>59.1±5.4</td>
<td>0.218</td>
</tr>
<tr>
<td>Gender (M/F)</td>
<td>17/3</td>
<td>16/4</td>
<td>14/6</td>
<td>0.503</td>
</tr>
<tr>
<td>Smoking load (pack-years)</td>
<td>38.6±2.1</td>
<td>29.5±2.3</td>
<td>-</td>
<td>0.006</td>
</tr>
<tr>
<td>FVC (% predicted)</td>
<td>72.5±3.3</td>
<td>85.7±3.6</td>
<td>105.2±2.4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FEV1 (% predicted)</td>
<td>41.3±2.6</td>
<td>83.1±3.3</td>
<td>101.0±2.5</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FEF25-75($) (% predicted)</td>
<td>46.7±2.6</td>
<td>82.1±1.0</td>
<td>84.4±1.8</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IL-6 (pg/ml)</td>
<td>393.6±107.2</td>
<td>88.5±23.8</td>
<td>90.5±3.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IL-8 (pg/ml)</td>
<td>6541.7±861.0</td>
<td>2717.4±632.7</td>
<td>385.9±30.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>TNF-α (pg/ml)</td>
<td>90.8±19.6</td>
<td>36.3±5.7</td>
<td>13.7±0.4</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

FVC=forced vital capacity, FEV1=forced expiratory volume in the first second, FEF25-75%=forced expiratory flow during middle half of the FVC, IL-6=interleukin-6, IL-8=interleukin-8, TNF-α=tumor necrosis factor-alpha. Data presented as mean±SEM of groups.

Figure 2: Correlation analysis between IL-8 levels in induced sputum and smoking load in group 2 ($r=0.646$, $P=0.002$)

Figure 3: Correlation analysis between TNF-α levels in induced sputum and smoking load in group 2 ($r=0.491$, $P=0.028$)
Bhowmik et al. established a correlation between the induced sputum IL-6 level and the smoking load. Takizawa et al. found a significant correlation between IL-8 mRNA levels and current amount of cigarette smoked. Kanazawa et al. found a correlation between the serum IL-8 level and the smoking load in patients with emphysema. In our study, correlation analysis revealed that there is moderate relationship between all relevant cytokine levels and smoking load in healthy smokers. Moreover, this relationship could not be shown in the COPD group at all. This finding is very interesting, and it implies that smoking load might be an indicator to predict the smokers who will develop COPD in future. Since a severe inflammation in the airways of COPD patients is already established and persists and progresses in a vicious cycle, cytokine levels are expectedly much higher in this group and patient-to-patient variation regarding the cytokine levels is not significant. Probably due to this fact, cytokine levels in the airways of COPD patients did not show any correlation with smoking load. Since long-term follow-up was not the scope of our study, we could not set any clinically significant cut-off value for the relevant cytokines and smoking load which might help to predict the healthy smokers in risk. However, we think that our findings lend remarkable support for designing further studies including long-term follow-up too in their methods.

We believe that our study has several strengths. Sputum analysis is used increasingly as a convenient, safe, and noninvasive method of assessing airway inflammation, both in terms of cellular indices and soluble mediators of inflammation. The repeatability, validity, and responsiveness of the method have been confirmed. Finally, measurement of cytokines in sputum supernatants is used as a research tool, but requires standardization of procedures and, generally, analytical validation. In our study, the inter assay and intra assay coefficients of variation of the all assays were less than 10%. In future, smokers will develop COPD that shows much higher in this group and patient variation off value for the healthy smokers. W e foresight that elevated cytokine levels and current amount of cigarette smoked. Increased smoking load and inflammatory responses, cytokines should be used evaluated to monitor clinical practice in the healthy smokers and COPD.

**Acknowledgments**

We are indebted to OZKAN KIZKIN for their assistance with the clinical aspects and data management. OZKAN KIZKIN, MD, died of leukemia (AML) diagnosed in Inonu University.

**References**


---

**Hacievliyagil, et al.: Airway inflammatory markers**


Announcement

iPhone App

A free application to browse and search the journal’s content is now available for iPhone/iPad. The application provides “Table of Contents” of the latest issues, which are stored on the device for future offline browsing. Internet connection is required to access the back issues and search facility. The application is Compatible with iPhone, iPod touch, and iPad and Requires iOS 3.1 or later. The application can be downloaded from http://itunes.apple.com/us/app/medknow-journals/id458064375?ls=1&mt=8. For suggestions and comments do write back to us.